Frecuencia de anticuerpos antipéptido cíclico citrulinado y factor reumatoide en pacientes con enfermedades reumatológicas de un centro de reumatología, Medellín, Colombia

Abstract

IntroductionThe initiation of therapy in rheumatoid arthritis prevents joint damage, but this requires an early diagnosis. The detection of rheumatoid factor and anti-cyclic citrullinated peptide is part of the initial diagnostic approach of patients with arthritis. ObjectiveTo determine the frequency of rheumatoid factor and anti-cyclic citrullinated peptide in patients with rheumatoid arthritis and other rheumatic diseases in patients of a rheumatology outpatient center in Medellin, Colombia. MethodsAn evaluation is made of the presence of rheumatoid factor and anti-cyclic citrullinated peptide in 246 subjects (64 with rheumatoid arthritis, 80 with other rheumatic diseases, 61 with osteoarthritis and 41 healthy or with fibromyalgia). ResultsIn rheumatoid arthritis patients the frequency of rheumatoid factor, anti-cyclic citrullinated peptide, and double positivity (rheumatoid factor and anti-cyclic citrullinated peptide simultaneously) was: 86%, 83% and 80%, respectively, and in other rheumatologic diseases it was: 12.5%, 6%, and 1%, respectively. No subjects with fibromyalgia, or healthy, tested positive for anti-cyclic citrullinated peptide, but up to 5% showed positivity for rheumatoid factor. ConclusionThe possibility of positivity for rheumatoid factor and anti-cyclic citrullinated peptides in diseases other than rheumatoid arthritis and in healthy people should be taken into account, and particularly rheumatoid factor.